Cancer markers are developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genome wide analyses of genome copy number and gene expression in breast cancer revealed 66 genes in the human chromosomal regions, 8p11, 11q13, 17q12, and 20q13 that were amplified. Diagnosis and assessment of amplification levels of genes shown to be amplified are useful in prediction of patient outcome of a of patient's response and drug resistance in breast cancer. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically breast cancer. Inhibitors of these genes will be useful therapies for treatment of these non-responsive cancers.
STATEMENT OF GOVERNMENTAL SUPPORT
 This invention was made during work supported by the National Cancer Institute, through Grants CA 58207 and CA 112970, and during work supported by the U.S. Department of Energy under Contract No. DE-ACO3-765F00098, now DE-ACO2-05CH11231. The government has certain rights in this invention.